SLNO
$33.22-0.39 (-1.16%)
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Recent News
A Look At Soleno Therapeutics (SLNO) Valuation As Oppenheimer Updates Vykat XR Launch And 2026 Sales Outlook
Soleno Therapeutics (SLNO) is back in focus after an Oppenheimer report flagged expectations for a slower US launch of Vykat XR, yet suggested 2026 sales could still come in ahead of earlier forecasts. See our latest analysis for Soleno Therapeutics. Those expectations arrive after a choppy year for Soleno, with a 30 day share price return of 12.7% and a 90 day share price return of 29.8%. The very large 3 year total shareholder return highlights how quickly sentiment has shifted around Vykat...
Sector Update: Health Care Stocks Slip Late Afternoon
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 1.6% and
Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says
Soleno Therapeutics (SLNO) is expected to see a slower US launch for Vykat XR, but 2026 sales could
H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 4, H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) from $120 to $100, while maintaining a Buy rating on the shares. The rating follows the company’s fiscal Q4 […]
Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy
Soleno Therapeutics, Inc. (NASDAQ:SLNO) ranks among the most shorted stocks to buy according to analysts. On February 25, Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted strong financial results for the fourth quarter of 2025, exceeding Wall Street estimates with EPS of $0.80, up from $0.61. Revenue also exceeded expectations, totaling $91.7 million compared to an expected $82.45 […]